Sweden
| Legal status | VERY PERMISSIVE |
|---|---|
| Key organization | Swedish Research Council |
| Policy | hESC research is allowed if IVF embryos of up to 14 days post-fertilisation are used or after SCNT. Therapeutic cloning is allowed if hereditary genetic traits remain unchanged. Reproductive cloning is banned. |
| Regulations | 1. Legal Regulation of Stem Cell Research 2002:119: http://www.regeringen.se/sb/d/108/a/2717 2. Regulations and Guidelines for the Use of Tissues and Cells in Healthcare and Clinical Research - SOSFS 2009:32: http://www.socialstyrelsen.se/sosfs/2009-32 |
| Legislation | Act on Genetic Integrity (2006:351) |
| Legislation Link | http://www.notisum.se/rnp/sls/lag/20060351.htm |
| Embryonic stem cell research policy | hESC reseach is allowed with the approval by a Regional Research Ethics Board. |
| Research with embryo | Research with embryo is allowed. In fact, the creation of embryo for research is also allowed with the approval by a Regional Research Ethics Board. |
| Embryo donation and cryopreservation | Embryo donation and cryopreservation is allowed in Sweden. |
| Somatic cell nuclear transfer | SCNT is allowed for research purposes. |
| Privacy and data protection | Patient Data Act: SFS 2008:355 (Swedish): http://www.notisum.se/rnp/sls/lag/20080355.htm |
Projects
- A Functional, Mature In vivo Human Ventricular Muscle Patch for Cardiomyopathy
- A PRECISION CELL REPLACEMENT STRATEGY FOR PARKINSON’S DISEASE
- Epigenetic drug action
- Genetic variation exposes regulators of blood cell formation in vivo in humans
- Patient-specific treatment for Parkinson’s disease using reprogrammed skin cells
- Resilience and Trigger Factors in Cardiac Arrhythmia: Risk Stratification and Drug Design
- STEM-PD trial: A multicentre, single arm, first in human, dose-escalation trial, investigating the safety and tolerability of intraputamenal transplantation of human embryonic stem cell derived dopaminergic cells for Parkinson’s disease (STEM-PD product)
Provider
- (WITHDRAWN) Cellartis AB
- (WITHDRAWN) Cellartis AB
- (WITHDRAWN) Karolinska Institutet
- (WITHDRAWN) The Sahlgrenska Academy at University of Gothenburg
- AstraZeneca AB
- Karolinska Institutet
- Karolinska Institutet - Department of Neuroscience
- Karolinska Institutet - Pan-Hammarström laboratory
- Karolinska Institutet - Stem Cell & Organoid Laboratory
- Karolinska Institutet - Stem Cell Laboratory
- Linköping University
- Lund University
- Skåne University Hospital
- Takara Bio Europe AB (former Cellartis)
- Takara Bio Europe AB (former Cellartis) - Human ES cell line derivation
- The Sahlgrenska Academy at University of Gothenburg
- University of Lund
- Uppsala University
- Uppsala University - Department of Immunology, Genetics and Pathology
- Uppsala University - Department of Medical Cell Biology
hESC Cell lines
- CEBe034-A-1
- CEBe001-A
- CEBe002-A
- CEBe006-A
- CEBe007-A
- CEBe008-A
- CEBe009-A
- CEBe010-A
- CEBe011-A
- CEBe012-A
- CEBe013-A
- CEBe014-A
- CEBe015-A
- CEBe016-A
- CEBe017-A
- CEBe018-A
- CEBe019-A
- CEBe020-A
- CEBe021-A
- CEBe022-A
- CEBe023-A
- CEBe024-A
- CEBe025-A
- CEBe026-A
- CEBe027-A
- CEBe028-A
- CEBe029-A
- CEBe030-A
- CEBe031-A
- CEBe032-A
- KIe001-A
- KIe002-A
- KIe003-A
- KIe004-A
- KIe005-A
- KIe006-A
- KIe007-A
- KIe008-A
- KIe009-A
- KIe010-A
- KIe011-A
- KIe012-A
- KIe013-A
- KIe014-A
- KIe015-A
- KIe016-A
- KIe017-A
- KIe018-A
- KIe019-A
- KIe020-A
- KIe021-A
- KIe022-A
- KIe023-A
- KIe024-A
- KIe025-A
- KIe026-A
- KIe027-A
- KIe028-A
- KIe029-A
- CEBe033-A
- CEBe034-A
- CEBe035-A
- KIe030-A
- KIe024-A-1
- KIe024-A-2
- KIe024-A-3
- KIe024-A-4
- KIe031-A
- KIe001-A-1
- KIe004-A-1
- KIe006-A-1
- KIe007-A-1
- KIe008-A-1
- KIe009-A-1
- KIe010-A-1
- KIe011-A-1
- KIe012-A-1
- KIe013-A-1
- KIe014-A-1
- KIe015-A-1
- KIe016-A-1
- KIe017-A-1
- KIe018-A-1
- KIe019-A-1
- KIe020-A-1
- KIe021-A-1
- KIe022-A-1
- KIe032-A
- KIe033-A
- CEBe002-A-1
- CEBe002-A-2
- CEBe002-A-3
- KIe034-A
- KIe035-A
- KIe051-A
- KIe053-A
- KIe054-A
- KIe055-A
- NOVOe001-A